نمایش پرونده ساده آیتم

dc.contributor.authorEntezari-Maleki, T
dc.contributor.authorMargedari, S
dc.contributor.authorGholami, K
dc.contributor.authorHadjibabaie, M
dc.contributor.authorOghazian, MB
dc.contributor.authorSalamzadeh, J
dc.contributor.authorKhoee, SH
dc.contributor.authorGhavamzadeh, A
dc.date.accessioned2018-08-26T08:54:23Z
dc.date.available2018-08-26T08:54:23Z
dc.date.issued2012
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54130
dc.description.abstractBackground and Aims: Adverse drug reactions (ADRs) are one of the major leading causes of death in the world. This study was designed and conducted because of the importance of adverse events in the cancer treatment setting and regarding this issue there is no study exploring adverse reactions of acute hematologie malignancy chemotherapy in Iranian population. Methods: This was a prospective, cross-sectional study performed at hematology-oncology and bone marrow transplantation research center. The inclusion criteria were all patients with acute hematologie malignancies such as ALL and AML, which were admitted over an 8 months period and were >15 years old age. Each ADR was categorized based on the WHO system organ classification. Results and Conclusion: The total number of detected ADRs was 310 in total of 105 patients. Eight patients (7.6%) experienced only one ADR, eleven patients (10.5%) experienced two ADRs and eighty-six of them (82%) experienced more than two ADRs. there was a significant relationship between the number of ADRs and type of hematologie malignancy. In this regard, the patients with AML malignancy showed more number of ADRs than with ALL malignancy (p<0.05) The Gastro-intestinal system disorders were the most common affected system-organ by chemotherapy regimens (33.5%). We suggest more well designed studies to determine the relation between the number of ADRs and study factors.
dc.language.isoEnglish
dc.relation.ispartofInternational Journal of Hematology-Oncology and Stem Cell Research
dc.subjectarsenic trioxide
dc.subjectcytarabine
dc.subjectidarubicin
dc.subjectvincristine
dc.subjectabnormal urine composition
dc.subjectacute granulocytic leukemia
dc.subjectacute lymphoblastic leukemia
dc.subjectadult
dc.subjectarticle
dc.subjectbackache
dc.subjectbleeding disorder
dc.subjectblood clotting disorder
dc.subjectbone marrow transplantation
dc.subjectcancer chemotherapy
dc.subjectcentral nervous system disease
dc.subjectcoughing
dc.subjectcross-sectional study
dc.subjectdisease association
dc.subjectdisease classification
dc.subjectedema
dc.subjectepistaxis
dc.subjectethnic group
dc.subjecteye pain
dc.subjectfemale
dc.subjectfever
dc.subjectgastrointestinal disease
dc.subjecthematology
dc.subjecthospital admission
dc.subjecthuman
dc.subjectinsomnia
dc.subjectIranian
dc.subjectlength of stay
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmental disease
dc.subjectmetabolic disorder
dc.subjectmultiple cycle treatment
dc.subjectmusculoskeletal disease
dc.subjectnausea
dc.subjectnutritional disorder
dc.subjectoncology
dc.subjectperipheral neuropathy
dc.subjectprospective study
dc.subjectrash
dc.subjectskin appendage disease
dc.subjectskin disease
dc.subjectthrombocyte disorder
dc.subjecturinary tract disease
dc.subjectvisual disorder
dc.subjectworld health organization
dc.titleEvaluation of chemotherapy toxicity in acute lymphoblastic and Myelogenous Leukemia
dc.typeArticle
dc.citation.volume6
dc.citation.issue2
dc.citation.spage8
dc.citation.epage12
dc.citation.indexScopus


فایلهای درون آیتم

Thumbnail

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم